Johnson & Johnson

Analyst thesis

Our recommendation is based on:

• A diversified portfolio: Johnson & Johnson’s (JNJ's) Innovative Medicine and MedTech segments span oncology, immunology, neuroscience, and cardiovascular medicine, with 28 products and platforms each generating over $1 billion in annual revenue. This product diversity cushions the impact of any single patent cliff and supports a more resilient growth profile.

• An oncology franchise targeting $50 billion in revenue by 2030: Darzalex and Carvykti continue to scale rapidly, with Carvykti sales up 62% year-on-year (YoY) in 1Q26, while further approvals (Tecvayli plus Darzalex Faspro) and Phase 3 data extend the growth runway well beyond the Stelara biosimilar cliff.

• A portfolio reshaped for higher growth: the planned separation of the DePuy Synthes orthopaedics business (targeted for mid-to-late 2027) is expected to lift the MedTech segment’s standalone growth rate and operating margin.

• A capital return tempered by litigation risk: 64 consecutive years of dividend increases reflect balance-sheet discipline, although unresolved talc litigation, roughly 76 000 pending cases, and a reserve with a present value of approximately $3.7 billion, remain an uncapped tail-risk overhang.

• Valuation: JNJ's current forward P:E of approximately 21x sits at a premium to both its five-year historical average and the broader pharma peer set (~16.8x), suggesting the market has already priced in a substantial portion of the anticipated oncology-led recovery, and the expected Stelara offset.